Harbin Jixianglong Biotech Semaglutide Rx Compounding Recall 2026 — 6 Packaging Sizes
Harbin Jixianglong Biotech Co. recalled Semaglutide for Rx compounding use nationwide in the United States. The recall cites CGMP deviations and failure to complete endotoxin validation before distribution. Healthcare providers and patients should stop using the product immediately and contact the company or a healthcare provider for guidance via email.